Switzerland is considering strategies to reduce U.S. tariffs imposed in August due to a trade deficit related to Swiss exports. The tariffs, currently at 39%, target Swiss imports like pharmaceuticals and gold.
To address this, Swiss officials are exploring options to enhance investment and production in the U.S. Measures under consideration include establishing or growing gold refining capacity within the United States. Additionally, there are discussions about expanding the production of pharmaceuticals in America to fully meet U.S. demand.
Increasing US Investments
The strategy also involves increasing the purchase of U.S. military goods and liquefied natural gas. These efforts are part of ongoing negotiations, with constructive talks reported between Swiss representatives and U.S. officials.
We remember the trade tensions from the Trump administration that led to 39% tariffs on Swiss goods. Those events forced a long-term shift in how Switzerland’s key industries, particularly gold and pharma, interact with the U.S. market. For traders today, the ripple effects from those historical negotiations are still influencing key assets.
Looking at the Swiss franc, the main driver now is the policy gap between the Swiss National Bank and the U.S. Federal Reserve. Recent data from August 2025 shows Swiss inflation holding steady near 1.8%, allowing the SNB to remain neutral, while the Fed is still signaling a hawkish stance to manage its own inflation numbers. This growing interest rate differential suggests traders should watch for continued strength in the USD/CHF pair, making long positions in futures contracts a viable strategy.
Structural Changes in Trade
The old proposal to build U.S.-based gold refineries did come to pass, fundamentally altering parts of the supply chain. U.S. Geological Survey data from the second quarter of 2025 confirmed that domestic gold refining capacity has increased by over 15% since 2022, reducing reliance on Swiss imports, which are down 8% year-over-year. This structural change means that implied volatility in gold options may not spike as dramatically on U.S.-Swiss trade news as it did back in the 2020s.
Swiss pharmaceutical giants also followed through on their plans to expand U.S. production, making their revenues less vulnerable to import tariffs. Major firms reported in mid-2025 that over 60% of their U.S. supply now originates from domestic plants, a significant jump from the 40% levels seen in 2020. Traders could see this as a stabilizing factor, making protective put options on these specific pharma stocks slightly cheaper than for their less localized European competitors.
